Clinical Trial Update: Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating picoplatin as second-line therapy for small cell lung cancer has completed. The sponsor is Poniard Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Picoplatin (picoplatin)

Snippet

Sponsor: Poniard Pharmaceuticals | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED